<p>在 Google 搜索和 AI 答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
<p>在 Google 上添加</p>
<ul>
<li>合并后的公司 SL Science Holding Limited 将在纳斯达克证券市场以 “SLBT” 作为股票代码开始交易</li>
<li>此交易为推进专有的伽马δ T 细胞基础的 “现成” 细胞疗法提供战略资本，针对包括胰腺癌和脑癌在内的实体肿瘤适应症</li>
<li>领导团队由经验丰富的高管和独立董事组成，以推动临床和商业增长的下一个阶段</li>
</ul>
<p>台北，台湾，2026 年 6 月 12 日（GLOBE NEWSWIRE）-- SL BIO 有限公司（“SL Bio” 或 “公司”），是一家总部位于台湾的生物医学公司，专注于开发创新的细胞和基因疗法，今天宣布与 Horizon Space Acquisition II Corp.（纳斯达克：HSPT）（“Horizon Space”）的业务合并已如期完成，这是一家公开交易的特殊目的收购公司。</p>
<p>该业务合并已于 2026 年 2 月 12 日的特别股东大会上获得 Horizon Space 股东的批准。业务合并完成后，SL Bio 和 Horizon Space 成为 SL Science Holding Limited 的全资子公司，该公司是一家开曼群岛控股公司（“SL Science”）。SL Science 的普通股预计将于 2026 年 6 月 15 日在纳斯达克全球市场以新的股票代码 “SLBT” 开始交易。</p>
<p><strong>战略影响与业务扩展</strong></p>
<p>此次业务合并的完成，隐含 SL Bio 的股权估值约为 55.68 亿美元，加上同时完成的 780 万美元 PIPE 融资，使 SL Science 能够加速其增长战略。</p>
<ul>
<li><strong>推进 “现成” 细胞疗法</strong>：该交易提供了必要的资本资源，以推动 SL Bio 的伽马δ T（“GDT”）细胞基础的专有细胞疗法平台通过临床前开发和计划中的临床试验，针对包括胰腺癌和脑癌在内的实体肿瘤适应症。与传统的自体疗法不同，SL Bio 的 GDT 细胞方法旨在创造可扩展的、现成的治疗方案，旨在解决当前肿瘤学市场面临的高成本和生产延迟问题。</li>
<li><strong>全球接入与并购杠杆</strong>：在纳斯达克证券市场交易使公司能够直接接触美国机构资本市场。这种增强的财务灵活性将对吸引顶级全球科学人才、促进未来潜在的战略收购以及确保全球许可合作伙伴关系至关重要。</li>
</ul>
<p><strong>扩展的执行领导团队和董事会</strong></p>
<p>为了支持其战略增长并保持作为美国上市公众实体的严格合规，SL Science 已正式建立了一套经验丰富的公司治理结构。SL Science 的首席执行官兼董事长 William Wang 将与首席财务官 Ray Leung、财务副总裁 Johnson Lau 和首席技术官兼董事 Ethan Shen 博士共同领导公司。SL Science 新组成的董事会包括独立董事 Joseph Levinson，他在会计和跨境公司治理方面拥有超过 25 年的专业经验，Qian（Hebe）Xu，拥有丰富的投资银行背景，以及 John C. General，提供收入确认、报告合规和 SOX 合规方面的专业知识。他们与独立董事 Kwo-Liang Chen 和 Mingche Liu 博士、博士共同组成了一个独特的董事会，能够指导公司的科学、监管和财务事务。</p>
<p>“今天标志着公司转型的重要里程碑，我们正式过渡为在纳斯达克上市的公司，” William Wang 先生说，“在全球肿瘤学市场，细胞疗法被广泛认为是最具变革性的治疗方法之一。然而，由于缺乏标准化、有限的生产能力和极高的成本，它尚未真正发展成一个全球行业。如果我们看看最成功的全球行业之一——半导体行业，他们的成功不仅仅是由技术驱动的，而是通过标准化流程、大规模生产和全球可扩展性实现的。”</p>
<p>“SL Bio 计划转变其平台，将这种工业逻辑，即标准化和可扩展制造引入细胞疗法。它旨在帮助将细胞疗法从高度定制的医疗程序转变为基于平台的、模块化、可扩展和可复制的商业模式。我们相信我们的技术不仅是一种新方法，也是一个全球平台。公司有信心我们的技术可能超越肿瘤学，进入全球免疫基础医学的未来。”</p>
<p>“今天的完成反映了成功完成了一项严谨的过程，以确定 Horizon Space 的合适合作伙伴。我们相信 SL Bio 结合了强大的科学能力和明确的长期愿景，使其成为一家引人注目的上市公司。” Mingyu Michael Li 先生说，“我们很高兴支持团队开始他们作为纳斯达克上市公司的下一个篇章。”</p>
<p><strong>顾问</strong></p>
<p>VCL Law LLP 和 Ogier 担任 SL Bio 的法律顾问。</p>
<p>Robinson &amp; Cole LLP 和 Maples Group 担任 Horizon Space 的法律顾问。</p>
<p><strong>关于 SL BIO 有限公司</strong></p>
<p>SL Bio 是一家生物医学公司，专注于开发创新的细胞和基因疗法。公司成立的宗旨是推动再生医学和癌症治疗，SL Bio 希望利用免疫细胞技术来针对癌症，从而为其产品提供广泛的医疗应用。凭借如伽马δ T 细胞等专有技术，针对包括胰腺癌和脑癌在内的实体肿瘤适应症，SL Bio 旨在创造细胞疗法，我们相信这些疗法有潜力在更广泛的生物制药行业中彻底改变细胞疗法和免疫肿瘤学领域。有关更多信息，请访问公司网站：https://www.slbtgroup.com/。</p>
<p><strong>关于 Horizon Space Acquisition II Corp.</strong></p>
<p>Horizon Space Acquisition II Corp.是一家空白支票公司，也通常被称为特殊目的收购公司（SPAC），其成立目的是为了与一个或多个企业或实体进行合并、股份交换、资产收购、股份购买、资本重组、重组或类似的商业组合。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据联邦证券法关于已完成商业组合和 SL Bio 业务的某些前瞻性声明。这些前瞻性声明通常通过 “相信”、“预测”、“期望”、“预期”、“估计”、“打算”、“战略”、“未来”、“机会”、“计划”、“可能”、“应该”、“将”、“会”、“将会”、“将继续”、“可能导致” 等类似词语来识别。前瞻性声明是关于未来事件的预测、展望和其他声明，这些声明基于当前的期望和假设，因此受到风险和不确定性的影响。许多因素可能导致实际未来事件与本文件中的前瞻性声明存在重大差异，包括但不限于：合并公司成功实施其商业计划和临床试验的能力；获得和维持其产品候选者所需的监管批准的能力；其再生医学产品实现商业化的潜力；以及实现商业组合预期收益的能力。合并公司不承担更新这些前瞻性声明的义务，除非适用法律要求。</p>
<p><strong>联系方式：</strong></p>
<p>SL BIO 有限公司</p>
<p>电话：+886-2-26516826</p>
<p>电子邮件：ir@sl-bio.com</p>
<p>WFS 投资者关系公司</p>
<p>电子邮件：services@wfsir.com</p>
<p>+1 628 283 9214</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjME5qTTFNaU0zTmpVNU9EVXpJelV3TURFMU56SXpOZz09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjME5qTTFNaU0zTmpVNU9EVXpJelV3TURFMU56SXpOZz09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTg0ODE4ZGUtNTU2MS00ZTAwLTgwZGMtYzM0NWM0ZThhNGNmLTUwMDE1NzIzNi0yMDI2LTA2LTEyLWVu/tiny/SL-Science-Holding-Limited.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTg0ODE4ZGUtNTU2MS00ZTAwLTgwZGMtYzM0NWM0ZThhNGNmLTUwMDE1NzIzNi0yMDI2LTA2LTEyLWVu/tiny/SL-Science-Holding-Limited.png"/></p>

HSPT

SLBT

<p>SL BIO 有限公司宣布与 Horizon Space Acquisition II Corp.完成业务合并，形成 SL Science Holding Limited。合并后的实体将于 2026 年 6 月 15 日起在纳斯达克全球市场以 “SLBT” 股票代码交易。此次交易为推进基于伽马δ T 细胞的实体肿瘤治疗提供了战略资本，并获得了进入美国机构资本市场的机会</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在 Google 搜索和 AI 答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在 Google 上添加</p>
</div><ul>
<li>Post-combination company, SL Science Holding Limited, to commence trading on the Nasdaq Stock Market under the ticker symbol “SLBT”</li>
<li>Transaction provides strategic capital to advance proprietary Gamma delta T cell-based &#34;off-the-shelf&#34; cellular therapies for solid tumor indications, including pancreatic and brain cancers</li>
<li>Leadership team bolstered by seasoned executives and highly experienced independent directors to drive the next phase of clinical and commercial growth</li>
</ul>
<div class="lb-trans"><ul>
<li>合并后的公司 SL Science Holding Limited 将在纳斯达克证券市场以 “SLBT” 作为股票代码开始交易</li>
<li>此交易为推进专有的伽马δ T 细胞基础的 “现成” 细胞疗法提供战略资本，针对包括胰腺癌和脑癌在内的实体肿瘤适应症</li>
<li>领导团队由经验丰富的高管和独立董事组成，以推动临床和商业增长的下一个阶段</li>
</ul>
</div><p>TAIPEI, Taiwan, June 12, 2026 (GLOBE NEWSWIRE) -- SL BIO Ltd. (“SL Bio” or the “Company”), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced the closing of its previously announced business combination with Horizon Space Acquisition II Corp. (Nasdaq: HSPT) (“Horizon Space”), a publicly traded special purpose acquisition company.</p>
<div class="lb-trans"><p>台北，台湾，2026 年 6 月 12 日（GLOBE NEWSWIRE）-- SL BIO 有限公司（“SL Bio” 或 “公司”），是一家总部位于台湾的生物医学公司，专注于开发创新的细胞和基因疗法，今天宣布与 Horizon Space Acquisition II Corp.（纳斯达克：HSPT）（“Horizon Space”）的业务合并已如期完成，这是一家公开交易的特殊目的收购公司。</p>
</div><p>The business combination was approved by Horizon Space shareholders at an extraordinary general meeting on February 12, 2026. Upon closing of the business combination, SL Bio and Horizon Space became wholly owned subsidiaries of SL Science Holding Limited, a Cayman Islands holding company (“SL Science”). The ordinary shares of SL Science are expected to commence trading on the Nasdaq Global Market under the new ticker symbol “SLBT” beginning on June 15, 2026.</p>
<div class="lb-trans"><p>该业务合并已于 2026 年 2 月 12 日的特别股东大会上获得 Horizon Space 股东的批准。业务合并完成后，SL Bio 和 Horizon Space 成为 SL Science Holding Limited 的全资子公司，该公司是一家开曼群岛控股公司（“SL Science”）。SL Science 的普通股预计将于 2026 年 6 月 15 日在纳斯达克全球市场以新的股票代码 “SLBT” 开始交易。</p>
</div><p><strong>Strategic Impact and Business Expansion</strong></p>
<div class="lb-trans"><p><strong>战略影响与业务扩展</strong></p>
</div><p>The completion of this business combination, which carries an implied equity valuation of SL Bio approximately $5.568 billion, combined with the concurrent closing of a $7.8 million PIPE financing, positions SL Science to accelerate its growth strategy.</p>
<div class="lb-trans"><p>此次业务合并的完成，隐含 SL Bio 的股权估值约为 55.68 亿美元，加上同时完成的 780 万美元 PIPE 融资，使 SL Science 能够加速其增长战略。</p>
</div><ul>
<li><strong>Advancing &#34;Off-the-Shelf&#34; Cellular Therapies</strong>: The transaction provides the capital resources necessary to progress SL Bio’s Gamma delta T (“GDT”) cell-based proprietary cellular therapy platforms through preclinical development and planned clinical trials targeting solid tumor indications, including pancreatic and brain cancers. Unlike traditional autologous therapies, SL Bio’s GDT cell approach is designed to create scalable, ready-to-use treatments, aiming to address the high costs and production delays currently facing the oncology market.</li>
<li><strong>Global Access and M&amp;A Leverage</strong>: Trading on the Nasdaq Stock Market grants the Company direct access to the U.S. institutional capital markets. This enhanced financial flexibility will be instrumental in attracting top-tier global scientific talent, facilitating potential future strategic acquisitions, and securing global licensing partnerships.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>推进 “现成” 细胞疗法</strong>：该交易提供了必要的资本资源，以推动 SL Bio 的伽马δ T（“GDT”）细胞基础的专有细胞疗法平台通过临床前开发和计划中的临床试验，针对包括胰腺癌和脑癌在内的实体肿瘤适应症。与传统的自体疗法不同，SL Bio 的 GDT 细胞方法旨在创造可扩展的、现成的治疗方案，旨在解决当前肿瘤学市场面临的高成本和生产延迟问题。</li>
<li><strong>全球接入与并购杠杆</strong>：在纳斯达克证券市场交易使公司能够直接接触美国机构资本市场。这种增强的财务灵活性将对吸引顶级全球科学人才、促进未来潜在的战略收购以及确保全球许可合作伙伴关系至关重要。</li>
</ul>
</div><p><strong>Expanded Executive Leadership and Board of Directors</strong></p>
<div class="lb-trans"><p><strong>扩展的执行领导团队和董事会</strong></p>
</div><p>To support its strategic growth and maintain rigorous compliance as a U.S.-listed public entity, SL Science has formalized a highly experienced corporate governance structure. William Wang, Chief Executive Officer and Chairman of SL Science, will lead the company alongside Ray Leung as Chief Financial Officer, Johnson Lau as Vice President of Finance, and Ethan Shen, Ph.D., as Chief Technology Officer and Director. SL Science’s newly constituted Board of Directors includes independent directors Joseph Levinson, bringing over 25 years of expertise in accounting and cross-border corporate governance, Qian (Hebe) Xu, offering an extensive background in investment banking and John C. General, providing expertise in revenue recognition, reporting compliance, and SOX compliance. They are joined by independent directors Kwo-Liang Chen and Mingche Liu, M.D., Ph.D., establishing a board uniquely equipped to guide the Company's scientific, regulatory, and financial initiatives.</p>
<div class="lb-trans"><p>为了支持其战略增长并保持作为美国上市公众实体的严格合规，SL Science 已正式建立了一套经验丰富的公司治理结构。SL Science 的首席执行官兼董事长 William Wang 将与首席财务官 Ray Leung、财务副总裁 Johnson Lau 和首席技术官兼董事 Ethan Shen 博士共同领导公司。SL Science 新组成的董事会包括独立董事 Joseph Levinson，他在会计和跨境公司治理方面拥有超过 25 年的专业经验，Qian（Hebe）Xu，拥有丰富的投资银行背景，以及 John C. General，提供收入确认、报告合规和 SOX 合规方面的专业知识。他们与独立董事 Kwo-Liang Chen 和 Mingche Liu 博士、博士共同组成了一个独特的董事会，能够指导公司的科学、监管和财务事务。</p>
</div><p>“Today marks a transformative milestone for the Company as we officially transition to a publicly traded company on Nasdaq,” said Mr. William Wang, “In the global oncology market, cell therapy is widely recognized as one of the most transformative approaches. However, it has yet to scale into a true global industry due to three core limitations: lack of standardization; limited manufacturing capacity; and extremely high costs. If we look at one of the most successful global industries—semiconductors—their success was not driven by technology alone, but by standardized processes, mass production, and global scalability.”</p>
<div class="lb-trans"><p>“今天标志着公司转型的重要里程碑，我们正式过渡为在纳斯达克上市的公司，” William Wang 先生说，“在全球肿瘤学市场，细胞疗法被广泛认为是最具变革性的治疗方法之一。然而，由于缺乏标准化、有限的生产能力和极高的成本，它尚未真正发展成一个全球行业。如果我们看看最成功的全球行业之一——半导体行业，他们的成功不仅仅是由技术驱动的，而是通过标准化流程、大规模生产和全球可扩展性实现的。”</p>
</div><p>“SL Bio plans to transform its platform to bring this industrial logic, namely standardization and scalable manufacturing to cell therapy. It will be intended to help shift cell therapy from a highly customized medical procedure into a platform-based, modular, scalable, and reproducible business model. We believe our technology is not just a new approach but also a global platform. The Company is confident that our technology may extend beyond oncology, into the future of immune-based medicine worldwide.”</p>
<div class="lb-trans"><p>“SL Bio 计划转变其平台，将这种工业逻辑，即标准化和可扩展制造引入细胞疗法。它旨在帮助将细胞疗法从高度定制的医疗程序转变为基于平台的、模块化、可扩展和可复制的商业模式。我们相信我们的技术不仅是一种新方法，也是一个全球平台。公司有信心我们的技术可能超越肿瘤学，进入全球免疫基础医学的未来。”</p>
</div><p>“Today’s closing reflects the successful completion of a disciplined process to identify the right partner for Horizon Space. We believe SL Bio combines strong scientific capacity with a clear long-term vision, making it a compelling public company.” said Mr. Mingyu Michael Li, “We are excited to support the team as they begin their next Chapter as a Nasdaq-listed Company.”</p>
<div class="lb-trans"><p>“今天的完成反映了成功完成了一项严谨的过程，以确定 Horizon Space 的合适合作伙伴。我们相信 SL Bio 结合了强大的科学能力和明确的长期愿景，使其成为一家引人注目的上市公司。” Mingyu Michael Li 先生说，“我们很高兴支持团队开始他们作为纳斯达克上市公司的下一个篇章。”</p>
</div><p><strong>Advisors</strong></p>
<div class="lb-trans"><p><strong>顾问</strong></p>
</div><p>VCL Law LLP and Ogier acted as legal advisors to SL Bio.</p>
<div class="lb-trans"><p>VCL Law LLP 和 Ogier 担任 SL Bio 的法律顾问。</p>
</div><p>Robinson &amp; Cole LLP and Maples Group acted as legal advisor to Horizon Space.</p>
<div class="lb-trans"><p>Robinson &amp; Cole LLP 和 Maples Group 担任 Horizon Space 的法律顾问。</p>
</div><p><strong>About SL BIO Ltd.</strong></p>
<div class="lb-trans"><p><strong>关于 SL BIO 有限公司</strong></p>
</div><p>SL Bio is a biomedical company specializing in developing innovative cellular and gene therapies. Established with a commitment to advancing regenerative medicine and cancer treatment, SL Bio hopes to utilize immune cell technologies to target cancer, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Gamma Delta T cells targeting solid tumor indications including pancreatic and brain cancers, SL Bio aims to create cellular therapies that we believe have the potential to revolutionize the cell therapy and immuno-oncology sector within the broader biopharmaceutical industry. For more information, please visit the company's website at: https://www.slbtgroup.com/.</p>
<div class="lb-trans"><p>SL Bio 是一家生物医学公司，专注于开发创新的细胞和基因疗法。公司成立的宗旨是推动再生医学和癌症治疗，SL Bio 希望利用免疫细胞技术来针对癌症，从而为其产品提供广泛的医疗应用。凭借如伽马δ T 细胞等专有技术，针对包括胰腺癌和脑癌在内的实体肿瘤适应症，SL Bio 旨在创造细胞疗法，我们相信这些疗法有潜力在更广泛的生物制药行业中彻底改变细胞疗法和免疫肿瘤学领域。有关更多信息，请访问公司网站：https://www.slbtgroup.com/。</p>
</div><p><strong>About Horizon Space Acquisition II Corp.</strong></p>
<div class="lb-trans"><p><strong>关于 Horizon Space Acquisition II Corp.</strong></p>
</div><p>Horizon Space Acquisition II Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.</p>
<div class="lb-trans"><p>Horizon Space Acquisition II Corp.是一家空白支票公司，也通常被称为特殊目的收购公司（SPAC），其成立目的是为了与一个或多个企业或实体进行合并、股份交换、资产收购、股份购买、资本重组、重组或类似的商业组合。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the completed business combination and the business of SL Bio. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: the ability of the combined company to successfully implement its business plans and clinical trials; the ability to obtain and maintain necessary regulatory approvals for its product candidates; the potential for its regenerative medicine products to reach commercialization; and the ability to recognize the anticipated benefits of the business combination. The combined company assumes no obligation to update these forward-looking statements, except as required by applicable law.</p>
<div class="lb-trans"><p>本新闻稿包含根据联邦证券法关于已完成商业组合和 SL Bio 业务的某些前瞻性声明。这些前瞻性声明通常通过 “相信”、“预测”、“期望”、“预期”、“估计”、“打算”、“战略”、“未来”、“机会”、“计划”、“可能”、“应该”、“将”、“会”、“将会”、“将继续”、“可能导致” 等类似词语来识别。前瞻性声明是关于未来事件的预测、展望和其他声明，这些声明基于当前的期望和假设，因此受到风险和不确定性的影响。许多因素可能导致实际未来事件与本文件中的前瞻性声明存在重大差异，包括但不限于：合并公司成功实施其商业计划和临床试验的能力；获得和维持其产品候选者所需的监管批准的能力；其再生医学产品实现商业化的潜力；以及实现商业组合预期收益的能力。合并公司不承担更新这些前瞻性声明的义务，除非适用法律要求。</p>
</div><p><strong>Contact Details:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>SL BIO Ltd.</p>
<div class="lb-trans"><p>SL BIO 有限公司</p>
</div><p>Tel: +886-2-26516826</p>
<div class="lb-trans"><p>电话：+886-2-26516826</p>
</div><p>Email: ir@sl-bio.com</p>
<div class="lb-trans"><p>电子邮件：ir@sl-bio.com</p>
</div><p>WFS Investor Relations Inc.</p>
<div class="lb-trans"><p>WFS 投资者关系公司</p>
</div><p>Email: services@wfsir.com</p>
<div class="lb-trans"><p>电子邮件：services@wfsir.com</p>
</div><p>+1 628 283 9214</p>
<div class="lb-trans"><p>+1 628 283 9214</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjME5qTTFNaU0zTmpVNU9EVXpJelV3TURFMU56SXpOZz09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTc0NjM1MiM3NjU5ODUzIzUwMDE1NzIzNg=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YTg0ODE4ZGUtNTU2MS00ZTAwLTgwZGMtYzM0NWM0ZThhNGNmLTUwMDE1NzIzNi0yMDI2LTA2LTEyLWVu/tiny/SL-Science-Holding-Limited.png" alt="" original-src="https://ml.globenewswire.com/media/YTg0ODE4ZGUtNTU2MS00ZTAwLTgwZGMtYzM0NWM0ZThhNGNmLTUwMDE1NzIzNi0yMDI2LTA2LTEyLWVu/tiny/SL-Science-Holding-Limited.png"/></p>

SL BIO 有限公司与 Horizon Space Acquisition II 宣布完成业务合并，并在纳斯达克全球市场上市 | SLBT 股票新闻